You are here
Perspectives in Lung Cancer 2017 - Webcasts on Demand
HOW I OPTIMIZE TREATMENT FOR MY NSCLC PATIENTS WITH ADVANCED AND AGGRESSIVE DISEASE
SILVIA NOVELLOSilvia Novello chairs this session on advanced NSCLC. The goal is to leave attendees better informed about: the reasons behind the limited treatment options, the advances towards better therapies and how to develop effective care plans using effective treatment sequencing and a multidisciplinary team.
How I select the right treatment for the right patient: histological and molecular profiling challenges
FERNANDO LÓPEZ-RÍOSFernando López-Ríos is a pathologist who in this session addresses current issues in collecting quality samples to achieve the most accurate diagnoses, and describes the current state of analytical testing for NSCLC and the benefits and limitations of the many analytical tools. He then reviews how to present pathology findings in the way that best benefits clinicians and patients.
How I optimize treatment for my patients with advanced non-squamous NSCLC: present options and future perspectives
JOACHIM AERTSJoachim Aerts reviews the ESMO clinical practice guidelines for diagnosis, treatment and follow-up of metastatic non-squamous NSCLC which were updated in 2016. He reviews the treatment algorithm for 1 st -line and 2 nd -line, and comments on promising upcoming clinical trial data. He looks at the newest clinical trial data on targeted therapies, and refers to the need to sequence these therapies in order to give patients the best care possible. He comments on the future of therapy combinations for this patient population.
How I optimize treatment for my patients with advanced squamous NSCLC: present options and future perspectives
LUIS PAZ-ARESLuis Paz-Ares reviews the current treatment strategies for squamous NSCLC and defines the differences between squamous and non-squamous NSCLC. He highlights the need for further research and better treatments, as even though small steps have been made in 1 st - and 2 nd -line, overall prognosis continues to be poor.